fusion

Fusion food, eco-friendly dining and healthy diets will be food tours trends for Summer 2024

The Do Eat Better Experience Outlook, an Italian company leading the "food tour" sector, opens an insight into all the market trends and forecasts for Summer 2024




fusion

Fusion Hippie LLC Recruits Linsey Beford Three Time Winner of Charlotte's Best CBD Store to Launch Their New Microdose and CBD Line, Marking Mainstream Brand Expansion

Poised to Debut Their New Cannabinoid Wellness Line, Fusion Hippie Taps In Well-Known CBD Veteran




fusion

SCCM Pod-435 Intracranial and Cerebral Perfusion Pressure Thresholds Associated with In-Hospital Mortality Across Pediatric Neurocritical Care

Targets for treatment of raised intracranial pressure or decreased cerebral perfusion pressure in pediatric neurocritical care are not well defined.




fusion

Claimant Confusion Leads to Lawsuits Against Comp Attorney

A claimants' attorney in Mississippi is facing a trio of lawsuits after having a client arrested for cashing what turned out to be the settlement check of another injured worker…




fusion

NRC Commissioners Wright and Crowell Visit Commonwealth Fusion Systems

NRCgov posted a photo:

Commissioner Wright and Commissioner Crowell visit Commonwealth Fusion Systems in Massachusetts. CFS is one of several firms seeking to use nuclear fusion (where hydrogen atoms combine to form helium) to generate electricity. The company is currently developing a system using powerful magnetic fields to control the extremely hot plasma that sustains a fusion reaction.

Visit the Nuclear Regulatory Commission's website at www.nrc.gov/.
Photo Usage Guidelines: www.flickr.com/people/nrcgov/
Privacy Policy: www.nrc.gov/site-help/privacy.html.
For additional information, or to comment on this photo contact us via e-mail at: OPA.Resource@nrc.gov.




fusion

Lay Science Writing Competition 2024: Evaluating umbilical cord blood transfusion efficacy and safety in neonates

Lay Science Writing Competition 2024: Evaluating umbilical cord blood transfusion efficacy and safety in neonates


Thursday, October 17, 2024 Mahsa Yazdanbakhsh

Our partnership with the Centre for Blood Research (CBR) at the University of British Columbia is helping to train the next generation of researchers in transfusion science. This blog post highlights just some of the achievements in education, training or knowledge mobilization accomplished by CBR trainees.   

Canadian Blood Services 2024 Lay Science Writing Competition offered in partnership with the Centre for Blood Research (CBR) provides research trainees an opportunity to exercise and enhance their science communication skills by sharing their research with lay audiences. The competition was open to research trainees in the broad Canadian Blood Services research network – including trainees that are directly funded by Canadian Blood Services, in laboratories that receive funding from Canadian Blood Services, and at the Centre for Blood Research in Vancouver. In this blog, graduate student Mahsa Yazdanbakhsh, author of the third prize-winning entry, provides some behind-the-scenes insights into the preparation of her submission. The full entry text is also shared below.  

Mahsa Yazdanbakhsh is a PhD candidate training in the laboratory of Canadian Blood Services senior scientist, Dr. Jason Acker at the University of Alberta.

Why did you choose to participate in the competition this year?  

I chose to participate in the competition because it gave me a chance to highlight important research in neonatal blood transfusion, specifically focusing on umbilical cord blood (UCB) transfusions for extremely premature newborns. I saw this as an opportunity to show how UCB could improve survival and outcomes for these vulnerable babies. Since I’m involved in this research, I felt it was important to share my insights and the potential benefits this work could bring to neonatal medicine. 

The theme this year was “Connecting science with society”; what did this theme mean to you?  

The theme was particularly meaningful to me because it emphasizes the importance of making scientific discoveries accessible and relevant to the broader public. For me, it’s about bridging the gap between complex research and real-world applications that can improve lives. In our work on umbilical cord blood transfusions for premature infants, the potential benefits go beyond the laboratory—they directly impact vulnerable newborns. This theme reminded me that research is not just about advancing knowledge within the scientific community, but also about ensuring that society understands and benefits from these advancements. By participating in this competition, I aimed to contribute to this connection, demonstrating how science can address critical healthcare challenges and ultimately improve outcomes for neonates. 

Did the writing process help you learn or discover something new about your research?  

Yes, the writing process helped me gain a new perspective on our research. It required me to step back and think about how to explain complex scientific concepts in a way that is clear and relatable to a wider audience. This helped me see my work from a different angle, focusing not just on the technical aspects, but also on the broader impact it could have on neonatal care. Writing about my research also reinforced the importance of effective science communication, reminding me that research isn't just about what happens in the lab, but how it can be applied to make a real difference in society. 

What tips would you share with others who are writing about research for lay audiences?  

When writing about research for lay audiences, I recommend simplifying complex ideas without losing the essence of the work. Break down the concepts into clear and simple language, but ensure key details remain intact. I suggest focusing on why the research matters by connecting it to real-world applications or benefits, helping readers understand its relevance. Avoid jargon whenever possible, and if you need to use technical terms, explain them in an accessible way. I also recommend using relatable examples to make complex concepts easier to grasp. Present the research in an engaging way, perhaps by telling a story or highlighting its human impact. 

Read the prize-winning entry in its entirety below...  

Evaluating umbilical cord blood transfusion efficacy and safety in neonates 

Imagine a small infant who was born prematurely and is having a hard time surviving in the outside world. These extraordinarily early newborns, referred to as ELGANs (Extremely Low Gestational Age Newborns), are born before 28 weeks of pregnancy and must fight a losing battle against anemia, a disorder in which there are insufficient healthy red blood cells in their blood to carry oxygen throughout their bodies. A common strategy used by physicians to win this conflict is blood transfusions. These transfusions now depend on adult donors' blood. This method, while life-saving, has limitations. Adult blood cells might not always meet these delicate babies' unique needs, which could occasionally result in complications and less positive results. But what if there was a more efficient method? 

Umbilical cord blood (UCB) has been proposed as a treatment for anemia in infants in the past. Fetal hemoglobin (HbF), a particular type of hemoglobin that is beneficial at carrying oxygen and protecting cells from harm, is rich in UCB. The fragility of fetal red blood cells and low volumes presented practical challenges that led to a decline in the use of UCB, despite its promising results. However, scientists are now looking again at this overlooked hero. They think that the secret to safer and more efficient treatments for premature babies may lie with UCB. According to recent research, UCB may be able to supply the necessary transfusions, and ongoing clinical trials are examining its advantages over adult blood.    

How to store UCB is a big obstacle when using it. UCB has a shorter life span than adult blood, which can be kept in storage for longer periods of time. Scientists are actively working on new methods to freeze and store UCB so it can be readily available when needed. This process is known as cryopreservation. Our research team has developed a meticulous method to freeze and thaw UCB. This technique, involving the addition and removal of a substance called glycerol, aids in protecting the blood cells during the freezing process. Having demonstrated the effectiveness of this method with adult blood, we are now adapting it for UCB.   

Our research is guided by three primary objectives: optimizing the freezing process, minimizing immune reactions, and assessing survival rates. By refining our freezing and thawing methods, our aim is to ensure that UCB cells remain healthy and functional. Furthermore, we seek to compare how the immune system responds to UCB and adult blood to ascertain the safety and efficacy of UCB transfusions. Lastly, we will evaluate the survival of UCB cells after cryopreservation and thawing, comparing them to adult blood cells. Success in these endeavors could offer a more potent treatment for anemia in premature babies, leading to improved health outcomes and fewer complications, thereby revolutionizing neonatal care and providing these vulnerable recipients with a stronger start in life. 

In conclusion, our research in Dr. Jason Acker's lab on UCB aims to address the critical needs of premature infants by optimizing cryopreservation techniques, understanding immune responses, and comparing the efficacy of UCB to adult blood. The potential benefits of utilizing UCB are immense, and if successful, this work could transform the landscape of neonatal transfusions, offering these vulnerable babies a better chance at a healthy start in life. 

About the author:

Mahsa's research is supported by the Canadian Blood Services Graduate Fellowship Program award. In her work, Mahsa focuses on optimizing blood manufacturing methods and investigating how to improve the efficacy of blood transfusion.  


Canadian Blood Services – Driving world-class innovation  

Through discovery, development and applied research, Canadian Blood Services drives world-class innovation in blood transfusion, cellular therapy and transplantation—bringing clarity and insight to an increasingly complex healthcare future. Our dedicated research team and extended network of partners engage in exploratory and applied research to create new knowledge, inform and enhance best practices, contribute to the development of new services and technologies, and build capacity through training and collaboration. Find out more about our research impact.   

The opinions reflected in this post are those of the author and do not necessarily reflect the opinions of Canadian Blood Services nor do they reflect the views of Health Canada or any other funding agency.  

Related blog posts


Tuesday, May 14, 2024
Abby Wolfe

The 2024 Canadian Blood Services’ Lay Science Writing Competition is open for submissions from research trainees in Canadian Blood Services’ research network until Friday, June 14, 2024. The theme this year is: “Connecting science with society”. Additional competition details available in this post!


Tuesday, July 09, 2024
Trainees

Canadian Blood Services research trainees reflect on the 2024 Canadian Society for Transfusion Medicine (CSTM) conference and their experience as planning committee members for Canadian Blood Services’ Research Day.


Thursday, January 26, 2023
Abby Wolfe

Announcing the winning entries from the Canadian Blood Services Research 180 Video Competition showcasing “Impact in motion”!




fusion

Wall of Confusion

Nine months into 2023, there is still a lot of work to do as far as reducing consumer confusion surrounding eco-friendly packaging – and reducing unnecessary packaging “waste” going to landfills.




fusion

Debra Lilley on Fusion Applications (Part 1 of 3)

Oracle ACE Director Debra Lilley of Fujitsu talks about her role as the Director and Deputy Chairperson of the UK Oracle User Group (UKOUG) and about the UKOUG development group's involvement in Oracle Fusion Applications.




fusion

Debra Lilley on Fusion Applications (Part 2 of 3)

Oracle ACE Director Debra Lilley of Fujitsu talks about Fusion Applications and their implications for Enterprise Architecture, and the importance of user experience.




fusion

Debra Lilley on Fusion Applications (Part 3 of 3)

Oracle ACE Director Debra Lilley of Fujitsu talks about closing the gap between IT and business, and about how business users should be able to use applications without having to think about the underlying technology.




fusion

A for Architecture: Oracle's Fusion Middleware A-Team - Part 1 of 3

Pete Farkas, Deepak Arora, and Derek Sharpe talk about the mission and focus of Oracle's Fusion Middleware A-Team.




fusion

A for Architecture: Oracle's Fusion Middleware A-Team - Part 2 of 3

Pete Farkas, Deepak Arora, and Derek Sharpe discuss the most common problems Oracle Fusion Middleware A-Team members encounter in the field.




fusion

A for Architecture: Oracle's Fusion Middleware A-Team - Part 3 of 3

Pete Farkas, Deepak Arora, and Derek Sharpe describe the interaction between Oracle Fusion Middleware A-Team and product teams, and the hazards of field assignments.




fusion

Digital transformation confusion risks paralysing SME manufacturers, says Made Smarter

Confusion around digital transformation is risking paralysis among SME manufacturers, says Made Smarter. Donna Edwards, director of the North West adoption programme, says businesses are hesitant to commit to change because they lack the confidence with technology and digital skills among leaders and employees.




fusion

Towards Ultrasound-guided Spinal Fusion Surgery

Location: Electronic Resource- 




fusion

CRISPR Immune Cells Not Only Survive, They Thrive After Infusion Into Cancer Patients

CRISPR Immune Cells Not Only Survive, They Thrive After Infusion Into Cancer Patients

In the first-ever (sanctioned) investigational use of multiple edits to the human genome, a study found that cells edited in three specific ways and then removed from patients and brought back into the lab setting were able to kill cancer months after their original manufacturing and infusion.

This is the first U.S. clinical trial to test the gene editing approach in humans, and the publication of this new data today follows on the initial report last year that researchers were able to use CRISPR/Cas9 technology to successfully edit three cancer patients' immune cells. The ongoing study is a cooperative between Tmunity Therapeutics, the Parker Institute for Cancer Immunotherapy, and the University of Pennsylvania. 

Patients on this trial were treated by Edward A. Stadtmauer, MD, section chief of Hematologic Malignancies at Penn, co-lead author on the study. The approach in this study is closely related to CAR T cell therapy, in which patient immune cells are engineered to fight cancer, but it has some key differences. Just like CAR T, researchers in this study began by collecting a patient's T cells from blood. However, instead of arming these cells with a receptor against a protein such as CD19, the team first used CRISPR/Cas9 editing to remove three genes. The first two edits removed a T cell's natural receptors so they can be reprogrammed to express a synthetic T cell receptor, allowing these cells to seek out and destroy tumors. The third edit removed PD-1, a natural checkpoint that sometimes blocks T cells from doing their job. 

Once the three genes are knocked out, a fourth genetic modification was accomplished using a lentivirus to insert the cancer-specific synthetic T cell receptor, which tells the edited T cells to target an antigen called NY-ESO-1. Previously published data show these cells typically survive for less than a week, but this new analysis shows the edited cells used in this study persisted, with the longest follow up at nine months. 

Several months after the infusion, researchers drew more blood and isolated the CRISPR-edited cells for study. When brought back into the lab setting, the cells were still able to kill tumors. 

The CRISPR-edited T cells used in this study are not active on their own like CAR T cells. Instead, they require the cooperation of a molecule known as HLA-A*02:01, which is only expressed in a subset of patients. This means that patients had to be screened ahead of time to make sure they were a match for the approach. Participants who met the requirements received other clinically-indicated therapy as needed while they waited for their cells to be manufactured. Once that process was completed, all three patients received the gene-edited cells in a single infusion after a short course of chemotherapy. Analysis of blood samples revealed that all three participants had the CRISPR-edited T cells take root and thrive in the patients. While none responded to the therapy, there were no treatment-related serious adverse events. 

CRISPR technology has not previously been tested in humans in the U.S. so the research team had to move through a comprehensive and rigorous series of institutional and federal regulatory approval steps, including approval by the National Institutes of Health's Recombinant DNA Research Advisory Committee and review by the U.S. Food and Drug Administration, as well as Penn's institutional review board and institutional biosafety committee. The entire process required more than two years.

 Researchers say these new data will open the door to later stage studies to investigate and extend this approach to a broader field beyond cancer, several of which are already planned at Penn.

sb admin Thu, 02/06/2020 - 14:52
Categories




fusion

Language is being twisted, with words turned into weapons, creating confusion as we debate what America should be

The weaponizing of words is poisoning our body politic…



  • Columns & Letters

fusion

DESIblitz Film Fusion Festival 2022 ready for launch

Showcasing Punjabi, Pakistani, Kashmiri, British and World films.




fusion

Malas comunicaciones del gobierno generan confusiones y que recomendaciones se le están haciendo al Gobierno en la comisión de relaciones ex

Escuche el programa de este martes 27 de agosto. La Luciérnaga, un espacio de humor y opinión de Caracol Radio que desde hace 31 años acompaña a sus oyentes en su regreso casa.




fusion

'Gavilán que si que no', el sencillo que fusiona la música llanera y del Pacífico




fusion

Suing Facebook over hate speech, nuclear fusion in sci-fi, invasive Strep A, British 'pantos', Tantura & more

Facebook faces a $2 billion lawsuit over hate speech; Expanse co-author Ty Franck on the role of nuclear fusion in sci-fi universes and the real world; making sense of the connection between respiratory virus outbreaks and invasive Strep A bacterial infections; a theatre director's bid to bring British holiday 'pantos' to Canada; Israeli documentary Tantura confronts an alleged massacre in a Palestinian village; and more.



  • Radio/Day 6

fusion

Cold Fusion 9 Application Mappings Access Denied

Cold Fusion 9 Mappings I have been trying to tackle this problem for some time now and have had little to no success with mapping directories directly in the Application.cfc. Trying to extend the Application.cfc seems to be an answer at this time, but not sure just yet. A particular post brought about the ideal […]




fusion

How to Handle Cold Fusion Errors – onError() Function and More

After lots of research surrounding the onMissingTemplate() function, cflog, and creating a custom error log, it became very event that the information you have would be great, I say great except; a server issue…. Source: Colorblind Programming <cfsetting showdebugoutput=”no” requesttimeout=”200″ /> <cfoutput> Server.ColdFusion.RootDir=#Server.ColdFusion.RootDir# <!— quick and dirty way of getting the file separator —> <cfif find(‘/’,Server.ColdFusion.RootDir)> […]




fusion

VMware Makes Workstation and Fusion Free For Everyone

An anonymous reader quotes a report from BleepingComputer: VMware has announced that its VMware Fusion and VMware Workstation desktop hypervisors are now free to everyone for commercial, educational, and personal use. In May, the company also made VMware Workstation Pro and Fusion Pro free for personal use, allowing students and home users to set up virtualized test labs and experiment with other OSs by running virtual machines and Kubernetes clusters on Windows, Linux, and macOS devices. Starting this week, the Pro versions and the two products will no longer be available under a paid subscription model. "Effective immediately, both VMware Fusion and VMware Workstation will transition away from the paid subscription model, meaning you can now utilize these tools without any cost. The paid versions of these offerings -- Workstation Pro and Fusion Pro -- are no longer available for purchase," said Broadcom product marketing director Himanshu Singh. "If you're currently under a commercial contract, you can rest easy knowing that your agreement will remain in effect until the end of your term. You will continue to receive the full level of service and enterprise-grade support as per your contract." While the free versions will include all the features available in the paid products, Broadcom will no longer provide users with support ticketing for troubleshooting. Broadcom plans to continue developing new features and improvements and ensure that updates are rolled out promptly. "We're actively investing in new features, usability improvements, and other valuable enhancements," Singh added. "Our engineering teams are committed to maintaining our high standards for stability, with timely updates and reliable performance." You can download VMware Fusion and VMware Workstation here (sign-in required).

Read more of this story at Slashdot.




fusion

A Versatile Nanotrap for Biochemical and Functional Studies with Fluorescent Fusion Proteins

Ulrich Rothbauer
Feb 1, 2008; 7:282-289
Research




fusion

Existence and uniqueness result for reaction-diffusion model of diffusive population dynamics

A. Kh. Khachatryan, Kh. A. Khachatryan and A. Zh. Narimanyan
Trans. Moscow Math. Soc. 83 (), 183-200.
Abstract, references and article information




fusion

High-order splitting finite element methods for the subdiffusion equation with limited smoothing property

Buyang Li, Zongze Yang and Zhi Zhou
Math. Comp. 93 (), 2557-2586.
Abstract, references and article information




fusion

Blow-up solutions of fractional diffusion equations with an exponential nonlinearity

Anh Tuan Nguyen, Tómas Caraballo and Nguyen Huy Tuan
Proc. Amer. Math. Soc. 152 (), 5175-5189.
Abstract, references and article information




fusion

The cation diffusion facilitator protein MamM's cytoplasmic domain exhibits metal-type dependent binding modes and discriminates against Mn2+ [Molecular Biophysics]

Cation diffusion facilitator (CDF) proteins are a conserved family of divalent transition metal cation transporters. CDF proteins are usually composed of two domains: the transmembrane domain, in which the metal cations are transported through, and a regulatory cytoplasmic C-terminal domain (CTD). Each CDF protein transports either one specific metal or multiple metals from the cytoplasm, and it is not known whether the CTD takes an active regulatory role in metal recognition and discrimination during cation transport. Here, the model CDF protein MamM, an iron transporter from magnetotactic bacteria, was used to probe the role of the CTD in metal recognition and selectivity. Using a combination of biophysical and structural approaches, the binding of different metals to MamM CTD was characterized. Results reveal that different metals bind distinctively to MamM CTD in terms of their binding sites, thermodynamics, and binding-dependent conformations, both in crystal form and in solution, which suggests a varying level of functional discrimination between CDF domains. Furthermore, these results provide the first direct evidence that CDF CTDs play a role in metal selectivity. We demonstrate that MamM's CTD can discriminate against Mn2+, supporting its postulated role in preventing magnetite formation poisoning in magnetotactic bacteria via Mn2+ incorporation.




fusion

Impact of the ISCHEMIA Trial on Stress Nuclear Myocardial Perfusion Imaging




fusion

Re: Decompression alone or with fusion for degenerative lumbar spondylolisthesis (Nordsten-DS): five year follow-up of a randomised, multicentre, non-inferiority trial




fusion

Emails: School choice org caused 'confusion' in voucher plan




fusion

Emails: School choice org caused 'confusion' in voucher plan




fusion

The library is open — really! But the closed stairs are causing confusion

The A.C. Hunter Public Library wants people in St. John’s to know that it’s open and accessible, despite how the entrance looks. The main staircase is under repair but there’s plenty of signs directing folks to other entrances. Still, librarians say people are judging this book by its cover and assuming the library is closed.




fusion

A Sporting Infusion for Ukrainian Summer Camps

OM Ukraine's sports team equips and trains churches in using non-traditional sports in their summer camps.




fusion

How Cadence Is Revolutionizing Automotive Sensor Fusion

The automotive industry is currently on the cusp of a radical evolution, steering towards a future where cars are not just vehicles but sophisticated, software-defined vehicles (SDV). This shift is marked by an increased reliance on automation and a significant increase in the use of sensors to improve safety and reliability. However, the increasing number of sensors has led to higher compute demands and poses challenges in managing a wide variety of data. The traditional method of using separate processors to manage each sensor's data is becoming obsolete. The current trends necessitate a unified processing system that can deal with multimodal sensor data, utilizing traditional Digital Signal Processing (DSP) and AI-driven algorithms. This approach allows for more efficient and reliable sensor fusion, significantly enhancing vehicle perception. Developers often face difficulties adhering to stringent power, performance, area, and cost (PPAC) and timing constraints while designing automotive SoCs.

Cadence, with its groundbreaking products and AI-powered processors, is enabling designers and automotive manufacturers to meet the future sensor fusion demands within the automotive sector. At the recent CadenceLive Silicon Valley 2024, Amol Borkar, product marketing director at Cadence, showcased the company's dedication and forward-thinking solutions in a captivating presentation titled "Addressing Tomorrow’s Sensor Fusion Needs in Automotive Computing with Cadence." This blog aims to encapsulate the pivotal takeaways from the presentation. If you missed the chance to watch this presentation live, please click here to watch it.

Significant Trends in the Automotive Market – Industry Landscape

We are witnessing a revolution in automotive technology. Innovations like occupant and driver monitoring systems (OMS, DMS), 4D radar imaging, LiDAR technology, and 360-degree view are pushing the boundaries of what's possible, leading us into an era of remarkable autonomy levels—ranging from no feet or hands required to eventually no eyes needed on the road.

Sensor Fusion and Increasing Processing Demands—Sensor fusion effectively integrates data from different sensors to help vehicles understand their surroundings better. Its main benefit is in overcoming the limitations of individual sensors. For example, cameras provide detailed visual information but struggle in low-light or lousy weather. On the other hand, radar is excellent at detecting objects in these conditions but lacks the detail that cameras provide. By combining the data from multiple sensors, automotive computing can take advantage of their strengths while compensating for their weaknesses, resulting in a more reliable and robust system overall.

 

One thing to note is that the increased number of sensors produces various data types, leading to more pre-processing.

On-Device Processing—As the industry moves towards autonomy, there is an increasing need for on-device data processing instead of cloud computing to enable vehicles to make informed decisions. Embracing on-device processing is a significant advancement for facilitating real-time decisions and avoiding round-trip latency.

AI Adoption—AI has become integral to automotive applications, driving safety, efficiency, and user experience advancements. AI models offer superior performance and adaptability, making future-proofing a crucial consideration for automotive manufacturers. AI significantly enhances sensor fusion algorithms, offering scalability and adaptability beyond traditional rule-based approaches. Neural networks enable various fusion techniques, such as early fusion, late fusion, and mid-fusion, to optimize the integration and processing of sensor data.

Future Sensor Fusion Needs

Automotive architectures are continually evolving. With current trends and AI integration into radar and sensor fusion applications, SoCs should be modular, flexible, and programmable to meet market demands.

Heterogeneous Architecture- Today's vehicles are loaded with various sensors, each with a unique processing requirement. Running the application on the most suitable processor is essential to achieve the best PPA. To meet such requirements, modern automotive solutions require a heterogeneous compute approach, integrating domain-specific digital signal processors (DSPs), neural processing units (NPUs), central processing unit (CPU) clusters, graphics processing unit (GPU) clusters, and hardware accelerator blocks. A balanced heterogeneous architecture gives the best PPA solution.

Flexibility and Programmability- The industry has come a long way from using computer vision algorithms such as HOG (Histogram Oriented Gradient) to detect people and objects, HAR classifier to detect faces, etc., to CNN and LSTM-based AI to Transformer models and graphical neural networks (GNN). AI has evolved tremendously over the last ten years and continues to evolve. To keep up with the evolving rate of AI, SoC design must be flexible and programmable for updates if needed in the future.

Addressing the Sensor Fusion Needs with Cadence

Cadence offers a complete suite of hardware and software products to address the increasing compute requirements in automotive. The comprehensive portfolio of Tensilica products built on the robust 32-bit RISC architecture caters to various automotive CPU and AI needs. What makes them particularly appealing is their scalability, flexibility, and configurability, offering many options to meet diverse needs.

 

The Xtensa family of products offers high-quality, power-efficient CPUs. Tensilica family also includes AI processors like Neo NPUs for the best power, performance, and area (PPA) for AI inference on devices or more extensive applications. Cadence also offers domain-specific products for DSPs such as HIFI DSPs, specialized DSPs and accelerators for radar and vision-based processing, and a general-purpose family of products for floating point applications.

The ConnX family offers a wide range of DSPs, from compact and low-power to high-performance, optimized for radar, lidar, and communications applications in ADAS, autonomous driving, V2X, 5G/LTE/4G, wireless communications, drones, and robotics. Tensilica's ISO26262 certification ensures compliance with automotive safety standards, making it a trusted partner for advanced automotive solutions. The Cadence NeuroWeave Software Development Kit (SDK) provides customers with a uniform, scalable, and configurable ML interface and tooling that significantly improves time to market and better prepares them for a continuously evolving AI market. Cadence Tensilica offers an entire ecosystem of software frameworks and compilers for all programming styles.

Tensilica's comprehensive software stack supports programming for DSPs, NPUs, and accelerators using C++, OpenCL, Halide, and various neural network approaches. Middleware libraries facilitate applications such as SLAM, radar processing, and Eigen libraries, providing robust support for automotive software development.

Conclusion

Cadence’s Tensilica products offer a development toolchain and various IPs tailored for the automotive industry, covering audio, vision, radar, unified DSPs, and NPUs. With ISO certification and a robust partner ecosystem, Tensilica solutions are designed to meet the future needs of automotive computing, ensuring safety, efficiency, and innovation.

Learn More

 

 




fusion

Nuclear fusion experiment overcomes two key operating hurdles

Two important barriers to a stable, powerful fusion reaction have been leapt by an experiment in a small tokamak reactor, but we don’t yet know if the technique will work in larger devices




fusion

Fusion reactors could create ingredients for a nuclear weapon in weeks

Concern over the risks of enabling nuclear weapons development is usually focused on nuclear fission reactors, but the potential harm from more advanced fusion reactors has been underappreciated




fusion

Hybrid design could make nuclear fusion reactors more efficient

Two types of fusion reactor called tokamaks and stellarators both have drawbacks – but a new design combining parts from both could offer the best of both worlds




fusion

Is the world's biggest fusion experiment dead after new delay to 2035?

ITER, a €20 billion nuclear fusion reactor under construction in France, will now not switch on until 2035 - a delay of 10 years. With smaller commercial fusion efforts on the rise, is it worth continuing with this gargantuan project?




fusion

Take a look behind the scenes at the world's largest fusion experiment

Photographer Enrico Sacchetti captures the power and potential of ITER, an international nuclear fusion experiment currently under construction in southern France




fusion

Confusion Over Diabetes Types Adds to Patients' Woes

Title: Confusion Over Diabetes Types Adds to Patients' Woes
Category: Health News
Created: 8/29/2012 10:05:00 AM
Last Editorial Review: 8/29/2012 12:00:00 AM




fusion

The Updated Registry of Fast Myocardial Perfusion Imaging with Next-Generation SPECT (REFINE SPECT 2.0)

The Registry of Fast Myocardial Perfusion Imaging with Next-Generation SPECT (REFINE SPECT) has been expanded to include more patients and CT attenuation correction imaging. We present the design and initial results from the updated registry. Methods: The updated REFINE SPECT is a multicenter, international registry with clinical data and image files. SPECT images were processed by quantitative software and CT images by deep learning software detecting coronary artery calcium (CAC). Patients were followed for major adverse cardiovascular events (MACEs) (death, myocardial infarction, unstable angina, late revascularization). Results: The registry included scans from 45,252 patients from 13 centers (55.9% male, 64.7 ± 11.8 y). Correlating invasive coronary angiography was available for 3,786 (8.4%) patients. CT attenuation correction imaging was available for 13,405 patients. MACEs occurred in 6,514 (14.4%) patients during a median follow-up of 3.6 y (interquartile range, 2.5–4.8 y). Patients with a stress total perfusion deficit of 5% to less than 10% (unadjusted hazard ratio [HR], 2.42; 95% CI, 2.23–2.62) and a stress total perfusion deficit of at least 10% (unadjusted HR, 3.85; 95% CI, 3.56–4.16) were more likely to experience MACEs. Patients with a deep learning CAC score of 101–400 (unadjusted HR, 3.09; 95% CI, 2.57–3.72) and a CAC of more than 400 (unadjusted HR, 5.17; 95% CI, 4.41–6.05) were at increased risk of MACEs. Conclusion: The REFINE SPECT registry contains a comprehensive set of imaging and clinical variables. It will aid in understanding the value of SPECT myocardial perfusion imaging, leverage hybrid imaging, and facilitate validation of new artificial intelligence tools for improving prediction of adverse outcomes incorporating multimodality imaging.




fusion

Arterial Spin-Labeling Perfusion Lightbulb Sign: An Imaging Biomarker of Pediatric Posterior Fossa Hemangioblastoma [CLINICAL PRACTICE]

BACKGROUND AND PURPOSE:

Hemangioblastoma is a rare vascular tumor that occurs within the central nervous system in children. Differentiating hemangioblastoma from other posterior fossa tumors can be challenging on imaging, and preoperative diagnosis can change the neurosurgical approach. We hypothesize that a "lightbulb sign" on the arterial spin-labeling (ASL) sequence (diffuse homogeneous intense hyperperfusion within the solid component of the tumor) will provide additional imaging finding to differentiate hemangioblastoma from other posterior fossa tumors.

MATERIALS AND METHODS:

In this retrospective comparative observational study, we only included pathology-proved cases of hemangioblastoma, while the control group consisted of other randomly selected pathology-proved posterior fossa tumors from January 2022 to January 2024. Two blinded neuroradiologists analyzed all applicable MRI sequences, including ASL sequence if available. ASL was analyzed for the lightbulb sign. Disagreements between the radiologists were resolved by a third pediatric neuroradiologist. 2 and Fisher exact test were used to analyze the data.

RESULTS:

Ninety-five patients were enrolled in the study; 57 (60%) were boys. The median age at diagnosis was 8 years old (interquartile range: 3–14). Of the enrolled patients, 8 had hemangioblastoma, and 87 had other posterior fossa tumors, including medulloblastoma (n = 31), pilocytic astrocytoma (n = 23), posterior fossa ependymoma type A (n = 16), and other tumors (n = 17). The comparison of hemangioblastoma versus nonhemangioblastoma showed that peripheral edema (P = .02) and T2-flow void (P = .02) favor hemangioblastoma, whereas reduced diffusion (low ADC) (P = .002) and ventricular system extension (P = .001) favor nonhemangioblastoma tumors. Forty-two cases also had ASL perfusion sequences. While high perfusion favors hemangioblastoma (P = .03), the lightbulb sign shows a complete distinction because all the ASL series of hemangioblastoma cases (n = 4) showed the lightbulb sign, whereas none of the nonhemangioblastoma cases (n = 38) showed the sign (P < .001).

CONCLUSIONS:

Lightbulb-like intense and homogeneous hyperperfusion patterns on ASL are helpful in diagnosing posterior fossa hemangioblastoma in children.




fusion

Diffusion Analysis of Intracranial Epidermoid, Head and Neck Epidermal Inclusion Cyst, and Temporal Bone Cholesteatoma [CLINICAL PRACTICE]

BACKGROUND AND PURPOSE:

Intracranial epidermoids temporal bone cholesteatomas, and head and neck epidermal inclusion cysts are typically slow-growing, benign conditions arising from ectodermal tissue. They exhibit increased signal on DWI. While much of the imaging literature describes these lesions as showing diffusion restriction, we investigated these qualitative signal intensities and interpretations of restricted diffusion with respect to normal brain structures. This study aimed to quantitatively evaluate the ADC values and histogram features of these lesions.

MATERIALS AND METHODS:

This retrospective study included children with histologically confirmed diagnoses of intracranial epidermoids, temporal bone cholesteatomas, or head and neck epidermal inclusion cysts. Lesions were segmented, and voxelwise calculation of ADC values was performed along with histogram analysis. ADC calculations were validated with a second analysis software to ensure accuracy. Normal brain ROIs—including the cerebellum, white matter, and thalamus—served as normal comparators. Correlational analysis and Bland-Altman plots assessed agreement among software tools for ADC calculations. Differences in the distribution of values between the lesions and normal brain tissues were assessed using the Wilcoxon rank sum and Kruskal-Wallis tests.

RESULTS:

Forty-eight pathology-proved cases were included in this study. Among them, 13 (27.1%) patients had intracranial epidermoids 14 (29.2%) had head and neck epidermal inclusion cysts, and 21 (43.7%) had temporal bone cholesteatomas. The mean age was 8.67 (SD, 5.30) years, and 27 (56.3%) were female. The intraclass correlation for absolute agreement for lesional ADC between the 2 software tools was 0.997 (95% CI, 0.995–0.998). The intracranial epidermoid head and neck epidermal inclusion cyst, and temporal bone cholesteatoma median ADC values were not significantly different (973.7 versus 875.7 versus 933.2 x 10–6 mm2/s, P = .265). However, the ADCs of the 3 types of lesions were higher than those of 3 normal brain tissue types (933 versus 766, x 10–6 mm2/s, P < .001).

CONCLUSIONS:

The ADC values of intracranial epidermoids, temporal bone cholesteatomas, and head and neck epidermal inclusion cysts are higher than those of normal brain regions. It is not accurate to simply classify these lesions as exhibiting restricted diffusion or reduced diffusivity without considering the tissue used for comparison. The observed hyperintensity on DWI compared with the brain is likely attributable to a relatively higher contribution of the T2 shinethrough effect.




fusion

MSMEs in confusion as govt is keeping mum on demand for extending implementation of revised Schedule M

Whilst the timeline set for adhering to the revised Schedule M of the Drugs and Cosmetics Act ends on December 31 for pharmaceutical companies with a turnover of less than Rs. 250 crore, the union ministry's




fusion

Oversimplification about integration of traditional & modern treatment systems creates confusion: Dr Kotecha

Oversimplification about integration of traditional and modern treatment systems often creates confusion among the stakeholders, and nobody understands the reality of the integration and what it is meant for, said Dr.




fusion

Is Fusion Commercialization in Sight? Not Yet, Says John Holdren

Great progress on nuclear fusion has been made, but commercialization of the technology before 2050 is unlikely, said John Holdren during a United States Energy Association press briefing. 





fusion

Interest on Capital consider as Capital Infusion

Hello Members,In one of the client case, he is partner at different firms. In one of the firm, the interest given to him on his Capital is consider as infusion of Capital since they had missed deducting TDS on the same. Now when we are filing his personal ITR, how do we con